SlideShare uma empresa Scribd logo
1 de 52
Baixar para ler offline
Dr. Shashwat Jani.
M. S. ( Obs – Gyn )
Diploma in Advance Laparoscopy.
Consultant Assistant Professor,
Smt. N.H.L. Municipal Medical College.
Sheth V. S. General Hospital , Ahmedabad.
Mobile : +91 99099 44160.
E-mail : drshashwatjani@gmail.com
1.Improvement of Follicular Growth
2.Increasing the Number of Follicles
3.Treatment of Anovulation (PCOS)
4.Better Timing
5.Improvement of Luteal Phase
24-Apr-17
Dr Shashwat Jani.
9909944160 2
Optimum Ovarian Stimulation
for IUI
 2 – 3 follicles with 18 – 19 mm size.
 Endometrium  9 mm thick & trilaminar.
 IUI between Cycle D13 and D16, 36-40
hrs. from HCG inj.
24-Apr-17
Dr Shashwat Jani.
9909944160 3
 Provides more number of follicles with good
quality.
 Timing of HCG injection predicts ovulation
better, so as to schedule IUI near ovulation time.
 C.O.H. offers more over for fertilization &
implantation, hence increases success.
 C.O.H. corrects subtle endocrinopathies which
block ovulation, implantation
24-Apr-17
Dr Shashwat Jani.
9909944160 4
 Retrograde Ejaculation
 Impotence or Ejaculatory Dysfunction
 Hypospadias
 Hypospermia (Low Volume)
 Non Liquefying / highly viscous semen
 ‘Subnormal’ semen parameters
 Seminal Antisperm Antibody
 Unexplained Infertility.
Dr Shashwat Jani.
9909944160 524-Apr-17
 Vaginismus
 Cervical Hostility
 Ovulatory Dysfunction
 Mild Endometriosis
 Allergy to seminal plasma
 Unexplained infertility
Dr Shashwat Jani.
9909944160 624-Apr-17
 Azoospermia with testicular failure
 Severely abnormal semen parameters Use
Discretion)
 Hereditary disease in man
 Severe untreatable Rh isoimmunisation in
wife
 Repeated failures with IVF/ICSI
 Single women, lesbian couples
Dr Shashwat Jani.
9909944160 724-Apr-17
Simple
Cost Effective
Minimal side effects
Best success rates
Patients requiring ovarian
stimulation or induction can be
categorized in two groups :
24-Apr-17
Dr Shashwat Jani.
9909944160 8
 In these patients there is an established
ovulatory pattern.
 Multiple studies have shown improved
pregnancy rates with ovarian stimulation
in these patients as compared to
nonstimulated natural cycles.
 Aim : Multiple follicle development
Dr Shashwat Jani.
9909944160 924-Apr-17
 20 – 30 % cases of female infertility
 Anovulatory patients are further divided
by WHO into 3 categories:
Group I: Hypogonadotrophic
hypogonadism
Group II: PCOS
Group III: Ovarian failure
 Aim : Monofollicular development
Dr Shashwat Jani.
9909944160 1024-Apr-17
Natural
cycle + IUI
3.3%
CC + IUI
9.5%
CC + hmG
+ IUI
13.3%
hmG + IUI
17.26%
Stimulation Protocol
24-Apr-17
Dr Shashwat Jani.
9909944160 11
Number of
follicles
Pregnancies
per cycle
(%)
ONE
5.7%
TWO
13.6%
THREE
16.3%
FOUR OR
MORE
13.9%
Number Of Follicles
Higher pregnancy rate with three preovulatory
follicles (Huttenen et al 1999)
24-Apr-17
Dr Shashwat Jani.
9909944160 12
D 2 FSH
( >10 mlU/ml is s/o low ovarian reserve )
AFC
Ovarian Volume
AMH
HSG / Lap
Dr Shashwat Jani.
9909944160 1324-Apr-17
1. Clomiphene citrate (CC)
2. Letrozole
3. Gonadotropins
4. Clomiphene with Gonadotrophins
5. Letrozole with gonadotrophins
6. Gonadotrophins with GnRH analogues
7. Gonadotrophins with GnRH antagonists
Dr Shashwat Jani.
9909944160 1424-Apr-17
 The cumulative pregnancy rate per couple
was 33% for IUI & COH, & 18% for IUI alone.
 COH has independent positive effect on
pregnancy rate when combined with IUI.
 In young patients without a prior pelvic surgery
& with good-post-wash semen quality COH
doubles IUI pregnancy rate.
Hendin B, Falcone T, Hallak J, Nelson D, Vemullapalli S, Goldberg J, et al. Effect of clinical &
semen charachteristics on efficacy of ovulatory stimulation in patients undergoing
IUI. J Assist Reprod Genet 200;17:189-93.24-Apr-17 15
Dr Shashwat Jani.
9909944160
 Most widely used
 Simple to use,
 Minimal side effects,
 Cost effective
24-Apr-17
Dr Shashwat Jani.
9909944160 16
Depletion of ER in pituitary
& hypothalamus due to
prolonged stimulation
Estrogen feedback loop gets
interrupted
FSH secretion increased
leading to multiple follicle
growth
Hypothalamus
Pituitary
CC binds to ER & depletes
receptor concentrations
More smaller follicles are rescued
Multiple follicles develop
estrogen –ve feedback
interrupted
FSH stimulation continues
1
2
3
4
5
17
Clomiphene citrate: Mechanism of action
Casper RF, et al. J Clin Endocrinol Metab. 2006; 91: 760-771.
 50-100mg per day for five days .
(up to 200mg per day)
 There is no difference in pregnancy
rate whether clomiphene is commenced on
day 2, 3, 4 or 5 of the cycle, although there is
perhaps a tendency to multiple follicular
development the closer the agent is
commenced to menses.
24-Apr-17
Dr Shashwat Jani.
9909944160 18
Pregnancy: 30%
Failure (no pregnancy despite
ovulation): 40%
Resistance: no ovulation: 25%
Antiestrogenic effect: 5%
Dr Shashwat Jani.
9909944160 1924-Apr-17
 Shows excellent result in ….
 CC Resistant
 CC Failure .
 Associated with thicker endometrium and
increased stromal blood flow, thereby providing
a better uterine environment more favorable for
implantation.
 Compared to CC, letrozole has been shown
to have higher pregnancy rates.
Dr Shashwat Jani.
9909944160 2024-Apr-17
• Inhibits aromatase in ovaries
& peripheral tissues reducing
estrogen levels
• Negative feed back being
active stimulates
hypothalamus-pituitary axis
• GnRH release produces FSH
• FSH-mediated stimulation of
follicle
• Rising estrogen level from
follicle
• suppresses FSH leaving a
single dominant-follicle
Hypothalamus
Pituitary
-ve feedback stimulation
Smaller follicles
undergo atresia
Single follicle develop
estrogen –ve feedback
FSH stimulation
1
2
3
4
6 androstenedione  estrogen
aromatase inhibition
GnRH released
Falling FSH
5
21
Letrozole: Mechanism of action
Casper RF, et al. J Clin Endocrinol Metab. 2006; 91: 760-771.
 Dose
 2.5 mg/day start cycle day 3-7, max 7.5 mg/day
(AL-Fadhli et al., 2006; Legro et al., 2014 N Engl J Med)
 Comparison with CC (Casper et al., 2006)
 High rate of monofolliculer
 No direct antiestrogenic adverse effect on
endometrium
 Shorter half-life (48hr and 2 wks)
 Lower serum E2
24-Apr-17
Dr Shashwat Jani.
9909944160 22
 In a recent study conducted by Badawy et al,
extended letrozole therapy (2.5mg daily from
day-1 of menses for 10 days) was used for CC
resistant PCOS women…
 Higher number of patients ovulated
 No of dominant follicles were more
 Pregnancy rates were significantly greater
 No extra cost
Dr Shashwat Jani.
9909944160 2324-Apr-17
 Reported by Mitwally et al.
 In this protocol letrozole was administered in
the step up doses consisting of one, two,
three, and four tablets of letrozole (2.5mg)
daily on menstrual cycle days 2, 3, 4 and 5
respectively.
 Multifollicular development
 Higher pregnancy rate
Dr Shashwat Jani.
9909944160 2424-Apr-17
 Indicated in :
- CC Failure
- Letrozole failure
- WHO Group 1 (Hypogonadotrophic hypogonadism )
 Cochrane ( 2007 ) …
“ Gonadotropins might be the most effective drugs
when IUI is combined with ovarian hyperstimulation .”
Dr Shashwat Jani.
9909944160 2524-Apr-17
 FSH or hMG administered daily from early in
the Menstrual Cycle.
 Monitoring with USG ( and Hormonal assays )
is mandatory
 Trigger ovulation with hCG when follicular
maturity attained
 Significantly improve pregnancy rates from
IUI, in contrast to natural cycle IUI.
 Risk of multiple pregnancy
Dr Shashwat Jani.
9909944160 2624-Apr-17
Advantages:
 high efficacy:
ovulation rate : >95 % per cycle
conception rate: 20 - 30 % per ovulatory cycle
Limitations:
 Serious complications can occur:
multiple pregnancies
▪ Twins 25%
▪ Higher order 5 %
ovarian hyperstimulation syndrome
long term complication ? ovarian cancer
 require intensive monitoring in specialist centre
 expensive
24-Apr-17
Dr Shashwat Jani.
9909944160 27
 Depends on the D2 LH / FSH /E2 levels.
 If LH FSH containing gonadotrophins are
indicated,
 Whereas if serum FSH (>10 mIU/ml),
LH + FSH is used for ovarian stimulation.
 For ovarian stimulation in patients with
hypogonadotrophic hypogonadism, a
combination of LH and FSH is used.
Dr Shashwat Jani.
9909944160 2824-Apr-17
A. Conventional regimen
B. Low dose step up regime
C. Step down regime
Dr Shashwat Jani.
9909944160 2924-Apr-17
Days 7 14 21 28
hCG
150 IU 112.5 IU 75 IU hCG
Foll.  10 mm
75-150 U daily
6 12
hCG
Foll.  16mm
37.5 IU 75 IU 112.5 IU 150 IU
Chronic Low dose Step up regimen
Step down
Conventional Regime
24-Apr-17
Dr Shashwat Jani.
9909944160 30
CC resistant OR CC Failure Cases
Started from D2 / D3
75 - 150 IU /day
Serial USG for monitoring
D 8 S. estradiol
Widely accepted protocol .
PR up to 30 %
Dr Shashwat Jani.
9909944160 3124-Apr-17
 Useful in PCOS
 AIM :
To find the “threshold“ level of FSH
which will lead to the development of a single
preovulatory follicle.
 Less complication
 But , unphysiological as FSH is very high in late
follicular phase compared to natural cycle.
Dr Shashwat Jani.
9909944160 3224-Apr-17
 Low starting dose (37.5- 75 units/day )
 Stepwise increase in subsequent doses
 E2 & USG on D7
 D8 E2 > 200 pg/ml OR follicle > 10mm
Ct. Same dose.
 If E2 or Follicle size not achieved on D8
increase dose by 37.5 IU /day .
Dr Shashwat Jani.
9909944160 3324-Apr-17
 HMG / FSH 150 IU/day from D2
 Continued till Dominant follicle become 10mm
on USG
 Decrease the dose .
 112.5 IU/day for next 3 days
 75 IU day till time of HCG.
Dr Shashwat Jani.
9909944160 3424-Apr-17
 Sequential use of CC f / b FSH or HMG.
 CC ( 100 mg ) 1 daily from D2 to D6.
 FSH or HMG ( 75 / 150 IU ) on D6 & D8.
 TVS on D8 onwards
 Additional FSH / HMG given.
Dr Shashwat Jani.
9909944160 3524-Apr-17
 Higher pregnancy rate than with CC alone .
 More cost effective, as the dosage of
gonadotrophins is reduced .
 Lesser multiple pregnancy rate than with
gonadotrophins alone .
 Lower incidence of OHSS, as compared to the
conventional regime.
 Kemmann E, Jones J R. Sequential clomiphene Citrate menotrophin therapy for
induction or enhancement of ovulation.Fertil Steril 1983;39:772-9
 Dickey R P, Olar T T, Taylor S N, Curole D N, Rye P H . Sequential clomiphene citrate and
Human menopausal Gonadotrophin for ovulation induction: comparison to clomiphene
citrate alone and human menopausal gonadotrophin alone.. Human Reprod 1993; 8:56-
59Dr Shashwat Jani.
9909944160 3624-Apr-17
 Good alternative to CC in patients with
unexplained infertility undergoing
gonadotrophin stimulated COH cycles
combined with IUI therapy.
 In a prospective nonrandomized study by
Mitwally and Casper it was shown that
aromatase inhibition with letrozole reduced
the dosage of FSH required for COH without
any undesirable antiestrogenic effects,
Dr Shashwat Jani.
9909944160 3724-Apr-17
 The pregnancy rate achieved was
also significantly lower in the
CC + FSH group (10.5%) compared
with the letrozole + FSH group (19.1%)
and FSH only group (18.7%).
Dr Shashwat Jani.
9909944160 3824-Apr-17
 In almost 15-20 % of cycles of CC or HMG
 Due to multi follicular development,
Estradiol Increases
Premature LH surge
Cycle Cancellation.
Dr Shashwat Jani.
9909944160 3924-Apr-17
 To avoid this endogenous LH interference,
Exogenous Gonadotrophins & GnRH
analogues are used for OI.
 Mainly useful in IVF.
 Recent Cochrane review has concluded that
GnRH analogues do not significantly
improve pregnancy rates in IUI.
Dr Shashwat Jani.
9909944160 4024-Apr-17
 Act by competitive inhibition of
GnRH receptors, which results in
rapid decline in FSH /LH levels, thus
preventing premature LH surge.
 Can be given in a single dose or daily
dose regimen.
Dr Shashwat Jani.
9909944160 4124-Apr-17
1. Lubeck Protocol:
Gonadotrophins are started as usual
and antagonist is started when the follicle
reaches a size of 14 mm, or from 6 day of
stimulation onwards in a dose of 0.25mg / day
till the day of HCG injection.
Dr Shashwat Jani.
9909944160 42
Diedrich K , Diedrich C , Santos E , Zoll C , Al-Hasani S , Reissmann T , et al. Suppression of the
endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist
Cetrorelix during ovarian stimulation . Hum Reprod. 1994; 9:788-791.
24-Apr-17
2. French Protocol :
Gonadotrophins are started as usual
and a single dose (3 mg) of antagonist is
given when serum E2 level is about 150-200
pg/ml and follicular size is 14 mm .
Dr Shashwat Jani.
9909944160 43
Olivennes F , Fanchin R , Bouchard P , de Ziegler D , Taieb J , Selva J , et al. . The single or dual
administration of the gonadotropin-releasing hormone antagonist Cetrorelix in an in vitro
fertilizationembryo transfer program. Fertil Steril. 1994;62:468
24-Apr-17
1. Allows the manipulation of follicular
development so that IUI can be avoided at
weekends without any detrimental effect on PR.
2. Compared to agonist , it is relatively simple
and inexpensive. There is no suppression of
oestrogen and the effects are easily reversible.
3. Antagonists are associated with lower
rates of OHSS.
Dr Shashwat Jani.
9909944160 4424-Apr-17
Dr Shashwat Jani.
9909944160 4524-Apr-17
 D2 TVS
 Serial TVS from D8  to look for follicular
development ( Number & Size ).
 Normally follicle grow 2 – 3 mm/day
 helps in determining exact time to trigger
ovulation
 Prevent OHSS
 Endometrium: look for thickness &
appearance.
 Triple line ET of > 9 – 10 mm is ideal .
Dr Shashwat Jani.
9909944160 4624-Apr-17
 In Natural Cycle : Serum E2 level correlates
with development of dominant follicle.
 In Stimulated cycle: it reflects the total
output of all developing follicle irrespective of
size.
 Problem : Inconvenience , Cost , daily Prick
 Mainly used in Gonadotrophin cycle on D8 ,
Value > 200 pg/ml  Good response.
Dr Shashwat Jani.
9909944160 4724-Apr-17
 > 4 follicles of > 16 mm OR > 8 follicles of > 12 mm
 Serum Estradiol
 > 1500 – 2000 pg / ml
Cancel the cycle
 If < 1500 pg/ ml  use GnRH analogue to trigger
ovulation
Dr Shashwat Jani.
9909944160 4824-Apr-17
 Premature LH surge is known to occur in
20 to 24% of patients undergoing ovarian
stimulation after the leading follicle reaches
16 mm.
 The LH surge can be detected either by
doing a daily blood or urinary LH assay, once
the leading follicle exceeds 16 mm.
 When LH surge detected  Inj. HCG given &
IUI planned.
Dr Shashwat Jani.
9909944160 4924-Apr-17
 Ideally 36 -38 after HCG administration
OR
After Confirmation of Ovulation.
50
Dr Shashwat Jani.
990994416024-Apr-17
 The HCG injection is necessary as the LH
secreted by the body may not be adequate
enough, to induce the necessary maturational
changes in all oocytes, if there are many
follicles in the ovary.
 Numerous urinary LH kits are available to
detect LH surge. They are easy to use and are
cost effective.
Dr Shashwat Jani.
9909944160 5124-Apr-17
24-Apr-17 52
Dr Shashwat Jani. +91
9909944160

Mais conteúdo relacionado

Mais procurados

Intrauterine Insemination UPDATE 2018
Intrauterine Insemination UPDATE 2018 Intrauterine Insemination UPDATE 2018
Intrauterine Insemination UPDATE 2018 Lifecare Centre
 
Recurrent pregnancy loss panel discussion
Recurrent pregnancy loss  panel discussionRecurrent pregnancy loss  panel discussion
Recurrent pregnancy loss panel discussionNiranjan Chavan
 
Recent advances in stimulation protocols
Recent advances in stimulation protocolsRecent advances in stimulation protocols
Recent advances in stimulation protocolsSandro Esteves
 
Controlled Ovarian Hyperstimulation With IUI
Controlled Ovarian Hyperstimulation With IUIControlled Ovarian Hyperstimulation With IUI
Controlled Ovarian Hyperstimulation With IUIBharati Dhorepatil
 
Ovulation induction
Ovulation inductionOvulation induction
Ovulation inductionsunitafeme
 
Gonadotrpin ovarian stimulation: Aboubakr elnashar
Gonadotrpin ovarian stimulation: Aboubakr elnasharGonadotrpin ovarian stimulation: Aboubakr elnashar
Gonadotrpin ovarian stimulation: Aboubakr elnasharAboubakr Elnashar
 
Agonists and antagonists in controlled ovarian stimulation
Agonists and antagonists in controlled ovarian stimulationAgonists and antagonists in controlled ovarian stimulation
Agonists and antagonists in controlled ovarian stimulationSandro Esteves
 
Individualizing Ovarian Stimulation Protocols for IVF
Individualizing Ovarian Stimulation Protocols for IVFIndividualizing Ovarian Stimulation Protocols for IVF
Individualizing Ovarian Stimulation Protocols for IVFSherInstitute
 
MANAGEMENT OF POOR RESPONDERS IN IVF BY DR SHASHWAT JANI
MANAGEMENT OF POOR RESPONDERS  IN IVF BY DR SHASHWAT JANIMANAGEMENT OF POOR RESPONDERS  IN IVF BY DR SHASHWAT JANI
MANAGEMENT OF POOR RESPONDERS IN IVF BY DR SHASHWAT JANIDR SHASHWAT JANI
 
Progestin-primed ovarian stimulation (PPOS) is a NEW DAW...
Progestin-primed ovarian stimulation (PPOS)                      is a NEW DAW...Progestin-primed ovarian stimulation (PPOS)                      is a NEW DAW...
Progestin-primed ovarian stimulation (PPOS) is a NEW DAW...Lifecare Centre
 
POOR RESPONDERS: Minimal Vs. Maximal stimulation
POOR RESPONDERS: Minimal Vs. Maximal stimulationPOOR RESPONDERS: Minimal Vs. Maximal stimulation
POOR RESPONDERS: Minimal Vs. Maximal stimulationAboubakr Elnashar
 
Optimizing iui results
Optimizing iui resultsOptimizing iui results
Optimizing iui resultsvandana bansal
 
PCOS - Ovulation Induction 1 - Dr Bharati Dhorepatil
PCOS - Ovulation Induction 1 - Dr Bharati DhorepatilPCOS - Ovulation Induction 1 - Dr Bharati Dhorepatil
PCOS - Ovulation Induction 1 - Dr Bharati DhorepatilBharati Dhorepatil
 
How to stimulate your patient for IVF / ICSI
How to stimulate your patient for IVF / ICSIHow to stimulate your patient for IVF / ICSI
How to stimulate your patient for IVF / ICSIHesham Al-Inany
 

Mais procurados (20)

Intrauterine Insemination UPDATE 2018
Intrauterine Insemination UPDATE 2018 Intrauterine Insemination UPDATE 2018
Intrauterine Insemination UPDATE 2018
 
Treatment of decreased ovarian reserve
Treatment of decreased ovarian reserveTreatment of decreased ovarian reserve
Treatment of decreased ovarian reserve
 
Recurrent pregnancy loss panel discussion
Recurrent pregnancy loss  panel discussionRecurrent pregnancy loss  panel discussion
Recurrent pregnancy loss panel discussion
 
GnRH antagonists
GnRH antagonistsGnRH antagonists
GnRH antagonists
 
Recent advances in stimulation protocols
Recent advances in stimulation protocolsRecent advances in stimulation protocols
Recent advances in stimulation protocols
 
Controlled Ovarian Hyperstimulation With IUI
Controlled Ovarian Hyperstimulation With IUIControlled Ovarian Hyperstimulation With IUI
Controlled Ovarian Hyperstimulation With IUI
 
Ovulation induction
Ovulation inductionOvulation induction
Ovulation induction
 
AN IDEAL OVULATION INDUCTION REGIMEN
AN IDEAL OVULATION INDUCTION REGIMENAN IDEAL OVULATION INDUCTION REGIMEN
AN IDEAL OVULATION INDUCTION REGIMEN
 
AMH & its Clinical Implications.pptx
AMH & its Clinical Implications.pptxAMH & its Clinical Implications.pptx
AMH & its Clinical Implications.pptx
 
Gonadotrpin ovarian stimulation: Aboubakr elnashar
Gonadotrpin ovarian stimulation: Aboubakr elnasharGonadotrpin ovarian stimulation: Aboubakr elnashar
Gonadotrpin ovarian stimulation: Aboubakr elnashar
 
Agonists and antagonists in controlled ovarian stimulation
Agonists and antagonists in controlled ovarian stimulationAgonists and antagonists in controlled ovarian stimulation
Agonists and antagonists in controlled ovarian stimulation
 
Ohss updated
Ohss updatedOhss updated
Ohss updated
 
Individualizing Ovarian Stimulation Protocols for IVF
Individualizing Ovarian Stimulation Protocols for IVFIndividualizing Ovarian Stimulation Protocols for IVF
Individualizing Ovarian Stimulation Protocols for IVF
 
Optimizing IUI Outcome
Optimizing IUI OutcomeOptimizing IUI Outcome
Optimizing IUI Outcome
 
MANAGEMENT OF POOR RESPONDERS IN IVF BY DR SHASHWAT JANI
MANAGEMENT OF POOR RESPONDERS  IN IVF BY DR SHASHWAT JANIMANAGEMENT OF POOR RESPONDERS  IN IVF BY DR SHASHWAT JANI
MANAGEMENT OF POOR RESPONDERS IN IVF BY DR SHASHWAT JANI
 
Progestin-primed ovarian stimulation (PPOS) is a NEW DAW...
Progestin-primed ovarian stimulation (PPOS)                      is a NEW DAW...Progestin-primed ovarian stimulation (PPOS)                      is a NEW DAW...
Progestin-primed ovarian stimulation (PPOS) is a NEW DAW...
 
POOR RESPONDERS: Minimal Vs. Maximal stimulation
POOR RESPONDERS: Minimal Vs. Maximal stimulationPOOR RESPONDERS: Minimal Vs. Maximal stimulation
POOR RESPONDERS: Minimal Vs. Maximal stimulation
 
Optimizing iui results
Optimizing iui resultsOptimizing iui results
Optimizing iui results
 
PCOS - Ovulation Induction 1 - Dr Bharati Dhorepatil
PCOS - Ovulation Induction 1 - Dr Bharati DhorepatilPCOS - Ovulation Induction 1 - Dr Bharati Dhorepatil
PCOS - Ovulation Induction 1 - Dr Bharati Dhorepatil
 
How to stimulate your patient for IVF / ICSI
How to stimulate your patient for IVF / ICSIHow to stimulate your patient for IVF / ICSI
How to stimulate your patient for IVF / ICSI
 

Semelhante a OVULATION INDUCTION FOR IUI BY DR SHASHWAT JANI

FIRST LINE THERAPY - CLOMIPHENE CITRATE & LETROZOLE BY DR SHASHWAT JANI
FIRST LINE THERAPY - CLOMIPHENE CITRATE & LETROZOLE  BY DR SHASHWAT JANIFIRST LINE THERAPY - CLOMIPHENE CITRATE & LETROZOLE  BY DR SHASHWAT JANI
FIRST LINE THERAPY - CLOMIPHENE CITRATE & LETROZOLE BY DR SHASHWAT JANIDR SHASHWAT JANI
 
Ovulation induction
Ovulation inductionOvulation induction
Ovulation inductionnermine amin
 
Medical Management of Ovarian Hyperstimulation Syndrome (OHSS) In 1500 IUI...
Medical Management of Ovarian Hyperstimulation Syndrome (OHSS) In  1500 IUI...Medical Management of Ovarian Hyperstimulation Syndrome (OHSS) In  1500 IUI...
Medical Management of Ovarian Hyperstimulation Syndrome (OHSS) In 1500 IUI...Lifecare Centre
 
ovarian stimulation- back to basics
ovarian stimulation- back to basicsovarian stimulation- back to basics
ovarian stimulation- back to basicsparul sehgal
 
Optimization of outcomes of .pptx
Optimization of outcomes of  .pptxOptimization of outcomes of  .pptx
Optimization of outcomes of .pptxDrRokeyaBegum
 
Ovulation induction in IUI
Ovulation induction in IUIOvulation induction in IUI
Ovulation induction in IUIPoonam Loomba
 
Medical managment of ovarian hyperstimulation
Medical managment of ovarian hyperstimulationMedical managment of ovarian hyperstimulation
Medical managment of ovarian hyperstimulationLifecare Centre
 
OVARIAN HYPERSTIMULATION SYNDROME (OHSS) : Our Experience in 580 IVF Cycles,...
OVARIAN HYPERSTIMULATION SYNDROME (OHSS)  : Our Experience in 580 IVF Cycles,...OVARIAN HYPERSTIMULATION SYNDROME (OHSS)  : Our Experience in 580 IVF Cycles,...
OVARIAN HYPERSTIMULATION SYNDROME (OHSS) : Our Experience in 580 IVF Cycles,...DelhiGynaecologistForum
 
Secrets for success of Intra Uterine Insemination (IUI)
Secrets for success of Intra Uterine Insemination (IUI)Secrets for success of Intra Uterine Insemination (IUI)
Secrets for success of Intra Uterine Insemination (IUI)Anu Test Tube Baby Centre
 
Any day start.pptx
Any day start.pptxAny day start.pptx
Any day start.pptxRaju Nair
 
J hum reprodsci6149-253271_000413
J hum reprodsci6149-253271_000413J hum reprodsci6149-253271_000413
J hum reprodsci6149-253271_000413NARENDRA MALHOTRA
 
EVIDENCE BASED PRACTICAL TIPS FOR LUTEAL PHASE SUPPORT BY DR SHASHWAT JANI
EVIDENCE BASED PRACTICAL TIPS FOR LUTEAL PHASE SUPPORT BY DR SHASHWAT JANIEVIDENCE BASED PRACTICAL TIPS FOR LUTEAL PHASE SUPPORT BY DR SHASHWAT JANI
EVIDENCE BASED PRACTICAL TIPS FOR LUTEAL PHASE SUPPORT BY DR SHASHWAT JANIDR SHASHWAT JANI
 
Predictive Factors influencing pregnancy rate after intrauterine insemination
Predictive Factors influencing pregnancy rate after intrauterine inseminationPredictive Factors influencing pregnancy rate after intrauterine insemination
Predictive Factors influencing pregnancy rate after intrauterine inseminationDrRokeyaBegum
 
Clomiphene Citrate Stimulation Protocol for Non IVF Cycle
Clomiphene Citrate Stimulation Protocol for Non IVF CycleClomiphene Citrate Stimulation Protocol for Non IVF Cycle
Clomiphene Citrate Stimulation Protocol for Non IVF CycleDr.Laxmi Agrawal Shrikhande
 

Semelhante a OVULATION INDUCTION FOR IUI BY DR SHASHWAT JANI (20)

FIRST LINE THERAPY - CLOMIPHENE CITRATE & LETROZOLE BY DR SHASHWAT JANI
FIRST LINE THERAPY - CLOMIPHENE CITRATE & LETROZOLE  BY DR SHASHWAT JANIFIRST LINE THERAPY - CLOMIPHENE CITRATE & LETROZOLE  BY DR SHASHWAT JANI
FIRST LINE THERAPY - CLOMIPHENE CITRATE & LETROZOLE BY DR SHASHWAT JANI
 
Ovulation induction
Ovulation inductionOvulation induction
Ovulation induction
 
Medical Management of Ovarian Hyperstimulation Syndrome (OHSS) In 1500 IUI...
Medical Management of Ovarian Hyperstimulation Syndrome (OHSS) In  1500 IUI...Medical Management of Ovarian Hyperstimulation Syndrome (OHSS) In  1500 IUI...
Medical Management of Ovarian Hyperstimulation Syndrome (OHSS) In 1500 IUI...
 
Ovarian stimulation
Ovarian stimulation Ovarian stimulation
Ovarian stimulation
 
ovarian stimulation- back to basics
ovarian stimulation- back to basicsovarian stimulation- back to basics
ovarian stimulation- back to basics
 
Optimization of outcomes of .pptx
Optimization of outcomes of  .pptxOptimization of outcomes of  .pptx
Optimization of outcomes of .pptx
 
Ovulation induction in IUI
Ovulation induction in IUIOvulation induction in IUI
Ovulation induction in IUI
 
Medical managment of ovarian hyperstimulation
Medical managment of ovarian hyperstimulationMedical managment of ovarian hyperstimulation
Medical managment of ovarian hyperstimulation
 
OVARIAN HYPERSTIMULATION SYNDROME (OHSS) : Our Experience in 580 IVF Cycles,...
OVARIAN HYPERSTIMULATION SYNDROME (OHSS)  : Our Experience in 580 IVF Cycles,...OVARIAN HYPERSTIMULATION SYNDROME (OHSS)  : Our Experience in 580 IVF Cycles,...
OVARIAN HYPERSTIMULATION SYNDROME (OHSS) : Our Experience in 580 IVF Cycles,...
 
ART in PCOS (1).pptx
ART in PCOS (1).pptxART in PCOS (1).pptx
ART in PCOS (1).pptx
 
Updated Slides
Updated SlidesUpdated Slides
Updated Slides
 
Secrets for success of Intra Uterine Insemination (IUI)
Secrets for success of Intra Uterine Insemination (IUI)Secrets for success of Intra Uterine Insemination (IUI)
Secrets for success of Intra Uterine Insemination (IUI)
 
Any day start.pptx
Any day start.pptxAny day start.pptx
Any day start.pptx
 
J hum reprodsci6149-253271_000413
J hum reprodsci6149-253271_000413J hum reprodsci6149-253271_000413
J hum reprodsci6149-253271_000413
 
EVIDENCE BASED PRACTICAL TIPS FOR LUTEAL PHASE SUPPORT BY DR SHASHWAT JANI
EVIDENCE BASED PRACTICAL TIPS FOR LUTEAL PHASE SUPPORT BY DR SHASHWAT JANIEVIDENCE BASED PRACTICAL TIPS FOR LUTEAL PHASE SUPPORT BY DR SHASHWAT JANI
EVIDENCE BASED PRACTICAL TIPS FOR LUTEAL PHASE SUPPORT BY DR SHASHWAT JANI
 
Pcos Panel Discussion
Pcos Panel DiscussionPcos Panel Discussion
Pcos Panel Discussion
 
D0343021025
D0343021025D0343021025
D0343021025
 
Follicular monitoring
Follicular monitoring Follicular monitoring
Follicular monitoring
 
Predictive Factors influencing pregnancy rate after intrauterine insemination
Predictive Factors influencing pregnancy rate after intrauterine inseminationPredictive Factors influencing pregnancy rate after intrauterine insemination
Predictive Factors influencing pregnancy rate after intrauterine insemination
 
Clomiphene Citrate Stimulation Protocol for Non IVF Cycle
Clomiphene Citrate Stimulation Protocol for Non IVF CycleClomiphene Citrate Stimulation Protocol for Non IVF Cycle
Clomiphene Citrate Stimulation Protocol for Non IVF Cycle
 

Mais de DR SHASHWAT JANI

STANDARD TECHNIQUES OF BREAST FEEDING BY DR SHASHWAT JANI.pptx
STANDARD TECHNIQUES OF BREAST FEEDING BY DR SHASHWAT JANI.pptxSTANDARD TECHNIQUES OF BREAST FEEDING BY DR SHASHWAT JANI.pptx
STANDARD TECHNIQUES OF BREAST FEEDING BY DR SHASHWAT JANI.pptxDR SHASHWAT JANI
 
EARLY PREGNANCY CHALLENGES IN ART BY DR SHASHWAT JANI
EARLY PREGNANCY CHALLENGES IN ART BY DR SHASHWAT JANIEARLY PREGNANCY CHALLENGES IN ART BY DR SHASHWAT JANI
EARLY PREGNANCY CHALLENGES IN ART BY DR SHASHWAT JANIDR SHASHWAT JANI
 
THYROID DISEASES IN PREGNANCY BY DR SHASHWAT JANI
THYROID DISEASES IN PREGNANCY BY DR SHASHWAT JANITHYROID DISEASES IN PREGNANCY BY DR SHASHWAT JANI
THYROID DISEASES IN PREGNANCY BY DR SHASHWAT JANIDR SHASHWAT JANI
 
IMPACT OF DEEP ENDOMETRIOSIS ON PREGNANCY & DELIVERY BY DR SHASHWAT JANI
IMPACT OF DEEP ENDOMETRIOSIS ON PREGNANCY & DELIVERY BY DR SHASHWAT JANIIMPACT OF DEEP ENDOMETRIOSIS ON PREGNANCY & DELIVERY BY DR SHASHWAT JANI
IMPACT OF DEEP ENDOMETRIOSIS ON PREGNANCY & DELIVERY BY DR SHASHWAT JANIDR SHASHWAT JANI
 
DENGUE IN PREGNANCY BY DR SHASHWAT JANI
DENGUE IN PREGNANCY BY DR SHASHWAT JANIDENGUE IN PREGNANCY BY DR SHASHWAT JANI
DENGUE IN PREGNANCY BY DR SHASHWAT JANIDR SHASHWAT JANI
 
DEBATE - SHORT CERVIX - OS TIGHTNING BY DR SHASHWAT JANI
DEBATE - SHORT CERVIX - OS TIGHTNING BY DR SHASHWAT JANIDEBATE - SHORT CERVIX - OS TIGHTNING BY DR SHASHWAT JANI
DEBATE - SHORT CERVIX - OS TIGHTNING BY DR SHASHWAT JANIDR SHASHWAT JANI
 
VASOMOTOR PROBLEMS IN MENOPAUSE BY DR SHASHWAT JANI
VASOMOTOR PROBLEMS IN MENOPAUSE BY DR SHASHWAT JANIVASOMOTOR PROBLEMS IN MENOPAUSE BY DR SHASHWAT JANI
VASOMOTOR PROBLEMS IN MENOPAUSE BY DR SHASHWAT JANIDR SHASHWAT JANI
 
TRANSFER OF A CRITICALLY ILL MOTHER BY DR SHASHWAT JANI
TRANSFER OF A CRITICALLY ILL MOTHER BY DR SHASHWAT JANITRANSFER OF A CRITICALLY ILL MOTHER BY DR SHASHWAT JANI
TRANSFER OF A CRITICALLY ILL MOTHER BY DR SHASHWAT JANIDR SHASHWAT JANI
 
PREVENTION OF PRETERM LABOUR - EVIDENCES FOR PROGESTERONE BY DR SHASHWAT JANI
PREVENTION OF PRETERM LABOUR - EVIDENCES FOR PROGESTERONE BY DR SHASHWAT JANIPREVENTION OF PRETERM LABOUR - EVIDENCES FOR PROGESTERONE BY DR SHASHWAT JANI
PREVENTION OF PRETERM LABOUR - EVIDENCES FOR PROGESTERONE BY DR SHASHWAT JANIDR SHASHWAT JANI
 
ECTOPIC PREGNANCY - FOGSI GUIDELINES BY DR SHASHWAT JANI
ECTOPIC PREGNANCY -  FOGSI GUIDELINES BY DR SHASHWAT JANIECTOPIC PREGNANCY -  FOGSI GUIDELINES BY DR SHASHWAT JANI
ECTOPIC PREGNANCY - FOGSI GUIDELINES BY DR SHASHWAT JANIDR SHASHWAT JANI
 
OVARIAN REJUVENATION - ROLE OF PLATELET RICH PLASMA THERAPY BY DR SHASHWAT JANI
OVARIAN REJUVENATION - ROLE OF PLATELET RICH PLASMA THERAPY BY DR SHASHWAT JANIOVARIAN REJUVENATION - ROLE OF PLATELET RICH PLASMA THERAPY BY DR SHASHWAT JANI
OVARIAN REJUVENATION - ROLE OF PLATELET RICH PLASMA THERAPY BY DR SHASHWAT JANIDR SHASHWAT JANI
 
OBSTETRIC PRACTICES IN PRESENT SCENARIO BY DR SHASHWAT JANI
OBSTETRIC PRACTICES IN PRESENT SCENARIO BY DR SHASHWAT JANIOBSTETRIC PRACTICES IN PRESENT SCENARIO BY DR SHASHWAT JANI
OBSTETRIC PRACTICES IN PRESENT SCENARIO BY DR SHASHWAT JANIDR SHASHWAT JANI
 
NONHORMONAL DRUGS FOR MALE INFERTILITY BY DR SHASHWAT JANI
NONHORMONAL DRUGS FOR MALE INFERTILITY BY DR SHASHWAT JANINONHORMONAL DRUGS FOR MALE INFERTILITY BY DR SHASHWAT JANI
NONHORMONAL DRUGS FOR MALE INFERTILITY BY DR SHASHWAT JANIDR SHASHWAT JANI
 
F.I.G.O. GUIDELINES & MEDICAL MANAGEMENT OF A.U.B. ( FOCUS ON PROGESTERONE ) ...
F.I.G.O. GUIDELINES & MEDICAL MANAGEMENT OF A.U.B. ( FOCUS ON PROGESTERONE ) ...F.I.G.O. GUIDELINES & MEDICAL MANAGEMENT OF A.U.B. ( FOCUS ON PROGESTERONE ) ...
F.I.G.O. GUIDELINES & MEDICAL MANAGEMENT OF A.U.B. ( FOCUS ON PROGESTERONE ) ...DR SHASHWAT JANI
 
MEDICAL MANAGEMENT OF ABNORMAL UTERINE BLEEDING BY DR SHASHWAT JANI
MEDICAL MANAGEMENT OF ABNORMAL UTERINE BLEEDING  BY DR SHASHWAT JANIMEDICAL MANAGEMENT OF ABNORMAL UTERINE BLEEDING  BY DR SHASHWAT JANI
MEDICAL MANAGEMENT OF ABNORMAL UTERINE BLEEDING BY DR SHASHWAT JANIDR SHASHWAT JANI
 
MANAGEMENT OF PREECLAMPSIA BY DR SHASHWAT JANI
MANAGEMENT OF PREECLAMPSIA BY DR SHASHWAT JANIMANAGEMENT OF PREECLAMPSIA BY DR SHASHWAT JANI
MANAGEMENT OF PREECLAMPSIA BY DR SHASHWAT JANIDR SHASHWAT JANI
 
MANAGEMENT OF GESTATIONAL DIABETES MELLITUS BY DR SHASHWAT JANI
MANAGEMENT OF GESTATIONAL DIABETES MELLITUS BY DR SHASHWAT JANIMANAGEMENT OF GESTATIONAL DIABETES MELLITUS BY DR SHASHWAT JANI
MANAGEMENT OF GESTATIONAL DIABETES MELLITUS BY DR SHASHWAT JANIDR SHASHWAT JANI
 
MANAGEMENT OF COMPLICATIONS OF HYSTEROSCOPY BY DR SHASHWAT JANI
MANAGEMENT OF COMPLICATIONS OF HYSTEROSCOPY BY DR SHASHWAT JANIMANAGEMENT OF COMPLICATIONS OF HYSTEROSCOPY BY DR SHASHWAT JANI
MANAGEMENT OF COMPLICATIONS OF HYSTEROSCOPY BY DR SHASHWAT JANIDR SHASHWAT JANI
 
GENITAL TB - HOW TO DIAGNOSE & WHEN TO TREAT BY DR SHASHWAT JANI
GENITAL TB - HOW TO DIAGNOSE  & WHEN TO TREAT  BY DR SHASHWAT JANIGENITAL TB - HOW TO DIAGNOSE  & WHEN TO TREAT  BY DR SHASHWAT JANI
GENITAL TB - HOW TO DIAGNOSE & WHEN TO TREAT BY DR SHASHWAT JANIDR SHASHWAT JANI
 
EXAMINATION OF MALE IN INFERTILITY - WHAT NOT TO MISS BY DR SHASHWAT JANI
EXAMINATION OF MALE IN INFERTILITY  - WHAT NOT TO MISS BY DR SHASHWAT JANIEXAMINATION OF MALE IN INFERTILITY  - WHAT NOT TO MISS BY DR SHASHWAT JANI
EXAMINATION OF MALE IN INFERTILITY - WHAT NOT TO MISS BY DR SHASHWAT JANIDR SHASHWAT JANI
 

Mais de DR SHASHWAT JANI (20)

STANDARD TECHNIQUES OF BREAST FEEDING BY DR SHASHWAT JANI.pptx
STANDARD TECHNIQUES OF BREAST FEEDING BY DR SHASHWAT JANI.pptxSTANDARD TECHNIQUES OF BREAST FEEDING BY DR SHASHWAT JANI.pptx
STANDARD TECHNIQUES OF BREAST FEEDING BY DR SHASHWAT JANI.pptx
 
EARLY PREGNANCY CHALLENGES IN ART BY DR SHASHWAT JANI
EARLY PREGNANCY CHALLENGES IN ART BY DR SHASHWAT JANIEARLY PREGNANCY CHALLENGES IN ART BY DR SHASHWAT JANI
EARLY PREGNANCY CHALLENGES IN ART BY DR SHASHWAT JANI
 
THYROID DISEASES IN PREGNANCY BY DR SHASHWAT JANI
THYROID DISEASES IN PREGNANCY BY DR SHASHWAT JANITHYROID DISEASES IN PREGNANCY BY DR SHASHWAT JANI
THYROID DISEASES IN PREGNANCY BY DR SHASHWAT JANI
 
IMPACT OF DEEP ENDOMETRIOSIS ON PREGNANCY & DELIVERY BY DR SHASHWAT JANI
IMPACT OF DEEP ENDOMETRIOSIS ON PREGNANCY & DELIVERY BY DR SHASHWAT JANIIMPACT OF DEEP ENDOMETRIOSIS ON PREGNANCY & DELIVERY BY DR SHASHWAT JANI
IMPACT OF DEEP ENDOMETRIOSIS ON PREGNANCY & DELIVERY BY DR SHASHWAT JANI
 
DENGUE IN PREGNANCY BY DR SHASHWAT JANI
DENGUE IN PREGNANCY BY DR SHASHWAT JANIDENGUE IN PREGNANCY BY DR SHASHWAT JANI
DENGUE IN PREGNANCY BY DR SHASHWAT JANI
 
DEBATE - SHORT CERVIX - OS TIGHTNING BY DR SHASHWAT JANI
DEBATE - SHORT CERVIX - OS TIGHTNING BY DR SHASHWAT JANIDEBATE - SHORT CERVIX - OS TIGHTNING BY DR SHASHWAT JANI
DEBATE - SHORT CERVIX - OS TIGHTNING BY DR SHASHWAT JANI
 
VASOMOTOR PROBLEMS IN MENOPAUSE BY DR SHASHWAT JANI
VASOMOTOR PROBLEMS IN MENOPAUSE BY DR SHASHWAT JANIVASOMOTOR PROBLEMS IN MENOPAUSE BY DR SHASHWAT JANI
VASOMOTOR PROBLEMS IN MENOPAUSE BY DR SHASHWAT JANI
 
TRANSFER OF A CRITICALLY ILL MOTHER BY DR SHASHWAT JANI
TRANSFER OF A CRITICALLY ILL MOTHER BY DR SHASHWAT JANITRANSFER OF A CRITICALLY ILL MOTHER BY DR SHASHWAT JANI
TRANSFER OF A CRITICALLY ILL MOTHER BY DR SHASHWAT JANI
 
PREVENTION OF PRETERM LABOUR - EVIDENCES FOR PROGESTERONE BY DR SHASHWAT JANI
PREVENTION OF PRETERM LABOUR - EVIDENCES FOR PROGESTERONE BY DR SHASHWAT JANIPREVENTION OF PRETERM LABOUR - EVIDENCES FOR PROGESTERONE BY DR SHASHWAT JANI
PREVENTION OF PRETERM LABOUR - EVIDENCES FOR PROGESTERONE BY DR SHASHWAT JANI
 
ECTOPIC PREGNANCY - FOGSI GUIDELINES BY DR SHASHWAT JANI
ECTOPIC PREGNANCY -  FOGSI GUIDELINES BY DR SHASHWAT JANIECTOPIC PREGNANCY -  FOGSI GUIDELINES BY DR SHASHWAT JANI
ECTOPIC PREGNANCY - FOGSI GUIDELINES BY DR SHASHWAT JANI
 
OVARIAN REJUVENATION - ROLE OF PLATELET RICH PLASMA THERAPY BY DR SHASHWAT JANI
OVARIAN REJUVENATION - ROLE OF PLATELET RICH PLASMA THERAPY BY DR SHASHWAT JANIOVARIAN REJUVENATION - ROLE OF PLATELET RICH PLASMA THERAPY BY DR SHASHWAT JANI
OVARIAN REJUVENATION - ROLE OF PLATELET RICH PLASMA THERAPY BY DR SHASHWAT JANI
 
OBSTETRIC PRACTICES IN PRESENT SCENARIO BY DR SHASHWAT JANI
OBSTETRIC PRACTICES IN PRESENT SCENARIO BY DR SHASHWAT JANIOBSTETRIC PRACTICES IN PRESENT SCENARIO BY DR SHASHWAT JANI
OBSTETRIC PRACTICES IN PRESENT SCENARIO BY DR SHASHWAT JANI
 
NONHORMONAL DRUGS FOR MALE INFERTILITY BY DR SHASHWAT JANI
NONHORMONAL DRUGS FOR MALE INFERTILITY BY DR SHASHWAT JANINONHORMONAL DRUGS FOR MALE INFERTILITY BY DR SHASHWAT JANI
NONHORMONAL DRUGS FOR MALE INFERTILITY BY DR SHASHWAT JANI
 
F.I.G.O. GUIDELINES & MEDICAL MANAGEMENT OF A.U.B. ( FOCUS ON PROGESTERONE ) ...
F.I.G.O. GUIDELINES & MEDICAL MANAGEMENT OF A.U.B. ( FOCUS ON PROGESTERONE ) ...F.I.G.O. GUIDELINES & MEDICAL MANAGEMENT OF A.U.B. ( FOCUS ON PROGESTERONE ) ...
F.I.G.O. GUIDELINES & MEDICAL MANAGEMENT OF A.U.B. ( FOCUS ON PROGESTERONE ) ...
 
MEDICAL MANAGEMENT OF ABNORMAL UTERINE BLEEDING BY DR SHASHWAT JANI
MEDICAL MANAGEMENT OF ABNORMAL UTERINE BLEEDING  BY DR SHASHWAT JANIMEDICAL MANAGEMENT OF ABNORMAL UTERINE BLEEDING  BY DR SHASHWAT JANI
MEDICAL MANAGEMENT OF ABNORMAL UTERINE BLEEDING BY DR SHASHWAT JANI
 
MANAGEMENT OF PREECLAMPSIA BY DR SHASHWAT JANI
MANAGEMENT OF PREECLAMPSIA BY DR SHASHWAT JANIMANAGEMENT OF PREECLAMPSIA BY DR SHASHWAT JANI
MANAGEMENT OF PREECLAMPSIA BY DR SHASHWAT JANI
 
MANAGEMENT OF GESTATIONAL DIABETES MELLITUS BY DR SHASHWAT JANI
MANAGEMENT OF GESTATIONAL DIABETES MELLITUS BY DR SHASHWAT JANIMANAGEMENT OF GESTATIONAL DIABETES MELLITUS BY DR SHASHWAT JANI
MANAGEMENT OF GESTATIONAL DIABETES MELLITUS BY DR SHASHWAT JANI
 
MANAGEMENT OF COMPLICATIONS OF HYSTEROSCOPY BY DR SHASHWAT JANI
MANAGEMENT OF COMPLICATIONS OF HYSTEROSCOPY BY DR SHASHWAT JANIMANAGEMENT OF COMPLICATIONS OF HYSTEROSCOPY BY DR SHASHWAT JANI
MANAGEMENT OF COMPLICATIONS OF HYSTEROSCOPY BY DR SHASHWAT JANI
 
GENITAL TB - HOW TO DIAGNOSE & WHEN TO TREAT BY DR SHASHWAT JANI
GENITAL TB - HOW TO DIAGNOSE  & WHEN TO TREAT  BY DR SHASHWAT JANIGENITAL TB - HOW TO DIAGNOSE  & WHEN TO TREAT  BY DR SHASHWAT JANI
GENITAL TB - HOW TO DIAGNOSE & WHEN TO TREAT BY DR SHASHWAT JANI
 
EXAMINATION OF MALE IN INFERTILITY - WHAT NOT TO MISS BY DR SHASHWAT JANI
EXAMINATION OF MALE IN INFERTILITY  - WHAT NOT TO MISS BY DR SHASHWAT JANIEXAMINATION OF MALE IN INFERTILITY  - WHAT NOT TO MISS BY DR SHASHWAT JANI
EXAMINATION OF MALE IN INFERTILITY - WHAT NOT TO MISS BY DR SHASHWAT JANI
 

Último

EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdfHongBiThi1
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project reportNARMADAPETROLEUMGAS
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectiondrhanifmohdali
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 

Último (20)

EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project report
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissection
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...
 

OVULATION INDUCTION FOR IUI BY DR SHASHWAT JANI

  • 1. Dr. Shashwat Jani. M. S. ( Obs – Gyn ) Diploma in Advance Laparoscopy. Consultant Assistant Professor, Smt. N.H.L. Municipal Medical College. Sheth V. S. General Hospital , Ahmedabad. Mobile : +91 99099 44160. E-mail : drshashwatjani@gmail.com
  • 2. 1.Improvement of Follicular Growth 2.Increasing the Number of Follicles 3.Treatment of Anovulation (PCOS) 4.Better Timing 5.Improvement of Luteal Phase 24-Apr-17 Dr Shashwat Jani. 9909944160 2
  • 3. Optimum Ovarian Stimulation for IUI  2 – 3 follicles with 18 – 19 mm size.  Endometrium  9 mm thick & trilaminar.  IUI between Cycle D13 and D16, 36-40 hrs. from HCG inj. 24-Apr-17 Dr Shashwat Jani. 9909944160 3
  • 4.  Provides more number of follicles with good quality.  Timing of HCG injection predicts ovulation better, so as to schedule IUI near ovulation time.  C.O.H. offers more over for fertilization & implantation, hence increases success.  C.O.H. corrects subtle endocrinopathies which block ovulation, implantation 24-Apr-17 Dr Shashwat Jani. 9909944160 4
  • 5.  Retrograde Ejaculation  Impotence or Ejaculatory Dysfunction  Hypospadias  Hypospermia (Low Volume)  Non Liquefying / highly viscous semen  ‘Subnormal’ semen parameters  Seminal Antisperm Antibody  Unexplained Infertility. Dr Shashwat Jani. 9909944160 524-Apr-17
  • 6.  Vaginismus  Cervical Hostility  Ovulatory Dysfunction  Mild Endometriosis  Allergy to seminal plasma  Unexplained infertility Dr Shashwat Jani. 9909944160 624-Apr-17
  • 7.  Azoospermia with testicular failure  Severely abnormal semen parameters Use Discretion)  Hereditary disease in man  Severe untreatable Rh isoimmunisation in wife  Repeated failures with IVF/ICSI  Single women, lesbian couples Dr Shashwat Jani. 9909944160 724-Apr-17
  • 8. Simple Cost Effective Minimal side effects Best success rates Patients requiring ovarian stimulation or induction can be categorized in two groups : 24-Apr-17 Dr Shashwat Jani. 9909944160 8
  • 9.  In these patients there is an established ovulatory pattern.  Multiple studies have shown improved pregnancy rates with ovarian stimulation in these patients as compared to nonstimulated natural cycles.  Aim : Multiple follicle development Dr Shashwat Jani. 9909944160 924-Apr-17
  • 10.  20 – 30 % cases of female infertility  Anovulatory patients are further divided by WHO into 3 categories: Group I: Hypogonadotrophic hypogonadism Group II: PCOS Group III: Ovarian failure  Aim : Monofollicular development Dr Shashwat Jani. 9909944160 1024-Apr-17
  • 11. Natural cycle + IUI 3.3% CC + IUI 9.5% CC + hmG + IUI 13.3% hmG + IUI 17.26% Stimulation Protocol 24-Apr-17 Dr Shashwat Jani. 9909944160 11
  • 12. Number of follicles Pregnancies per cycle (%) ONE 5.7% TWO 13.6% THREE 16.3% FOUR OR MORE 13.9% Number Of Follicles Higher pregnancy rate with three preovulatory follicles (Huttenen et al 1999) 24-Apr-17 Dr Shashwat Jani. 9909944160 12
  • 13. D 2 FSH ( >10 mlU/ml is s/o low ovarian reserve ) AFC Ovarian Volume AMH HSG / Lap Dr Shashwat Jani. 9909944160 1324-Apr-17
  • 14. 1. Clomiphene citrate (CC) 2. Letrozole 3. Gonadotropins 4. Clomiphene with Gonadotrophins 5. Letrozole with gonadotrophins 6. Gonadotrophins with GnRH analogues 7. Gonadotrophins with GnRH antagonists Dr Shashwat Jani. 9909944160 1424-Apr-17
  • 15.  The cumulative pregnancy rate per couple was 33% for IUI & COH, & 18% for IUI alone.  COH has independent positive effect on pregnancy rate when combined with IUI.  In young patients without a prior pelvic surgery & with good-post-wash semen quality COH doubles IUI pregnancy rate. Hendin B, Falcone T, Hallak J, Nelson D, Vemullapalli S, Goldberg J, et al. Effect of clinical & semen charachteristics on efficacy of ovulatory stimulation in patients undergoing IUI. J Assist Reprod Genet 200;17:189-93.24-Apr-17 15 Dr Shashwat Jani. 9909944160
  • 16.  Most widely used  Simple to use,  Minimal side effects,  Cost effective 24-Apr-17 Dr Shashwat Jani. 9909944160 16
  • 17. Depletion of ER in pituitary & hypothalamus due to prolonged stimulation Estrogen feedback loop gets interrupted FSH secretion increased leading to multiple follicle growth Hypothalamus Pituitary CC binds to ER & depletes receptor concentrations More smaller follicles are rescued Multiple follicles develop estrogen –ve feedback interrupted FSH stimulation continues 1 2 3 4 5 17 Clomiphene citrate: Mechanism of action Casper RF, et al. J Clin Endocrinol Metab. 2006; 91: 760-771.
  • 18.  50-100mg per day for five days . (up to 200mg per day)  There is no difference in pregnancy rate whether clomiphene is commenced on day 2, 3, 4 or 5 of the cycle, although there is perhaps a tendency to multiple follicular development the closer the agent is commenced to menses. 24-Apr-17 Dr Shashwat Jani. 9909944160 18
  • 19. Pregnancy: 30% Failure (no pregnancy despite ovulation): 40% Resistance: no ovulation: 25% Antiestrogenic effect: 5% Dr Shashwat Jani. 9909944160 1924-Apr-17
  • 20.  Shows excellent result in ….  CC Resistant  CC Failure .  Associated with thicker endometrium and increased stromal blood flow, thereby providing a better uterine environment more favorable for implantation.  Compared to CC, letrozole has been shown to have higher pregnancy rates. Dr Shashwat Jani. 9909944160 2024-Apr-17
  • 21. • Inhibits aromatase in ovaries & peripheral tissues reducing estrogen levels • Negative feed back being active stimulates hypothalamus-pituitary axis • GnRH release produces FSH • FSH-mediated stimulation of follicle • Rising estrogen level from follicle • suppresses FSH leaving a single dominant-follicle Hypothalamus Pituitary -ve feedback stimulation Smaller follicles undergo atresia Single follicle develop estrogen –ve feedback FSH stimulation 1 2 3 4 6 androstenedione  estrogen aromatase inhibition GnRH released Falling FSH 5 21 Letrozole: Mechanism of action Casper RF, et al. J Clin Endocrinol Metab. 2006; 91: 760-771.
  • 22.  Dose  2.5 mg/day start cycle day 3-7, max 7.5 mg/day (AL-Fadhli et al., 2006; Legro et al., 2014 N Engl J Med)  Comparison with CC (Casper et al., 2006)  High rate of monofolliculer  No direct antiestrogenic adverse effect on endometrium  Shorter half-life (48hr and 2 wks)  Lower serum E2 24-Apr-17 Dr Shashwat Jani. 9909944160 22
  • 23.  In a recent study conducted by Badawy et al, extended letrozole therapy (2.5mg daily from day-1 of menses for 10 days) was used for CC resistant PCOS women…  Higher number of patients ovulated  No of dominant follicles were more  Pregnancy rates were significantly greater  No extra cost Dr Shashwat Jani. 9909944160 2324-Apr-17
  • 24.  Reported by Mitwally et al.  In this protocol letrozole was administered in the step up doses consisting of one, two, three, and four tablets of letrozole (2.5mg) daily on menstrual cycle days 2, 3, 4 and 5 respectively.  Multifollicular development  Higher pregnancy rate Dr Shashwat Jani. 9909944160 2424-Apr-17
  • 25.  Indicated in : - CC Failure - Letrozole failure - WHO Group 1 (Hypogonadotrophic hypogonadism )  Cochrane ( 2007 ) … “ Gonadotropins might be the most effective drugs when IUI is combined with ovarian hyperstimulation .” Dr Shashwat Jani. 9909944160 2524-Apr-17
  • 26.  FSH or hMG administered daily from early in the Menstrual Cycle.  Monitoring with USG ( and Hormonal assays ) is mandatory  Trigger ovulation with hCG when follicular maturity attained  Significantly improve pregnancy rates from IUI, in contrast to natural cycle IUI.  Risk of multiple pregnancy Dr Shashwat Jani. 9909944160 2624-Apr-17
  • 27. Advantages:  high efficacy: ovulation rate : >95 % per cycle conception rate: 20 - 30 % per ovulatory cycle Limitations:  Serious complications can occur: multiple pregnancies ▪ Twins 25% ▪ Higher order 5 % ovarian hyperstimulation syndrome long term complication ? ovarian cancer  require intensive monitoring in specialist centre  expensive 24-Apr-17 Dr Shashwat Jani. 9909944160 27
  • 28.  Depends on the D2 LH / FSH /E2 levels.  If LH FSH containing gonadotrophins are indicated,  Whereas if serum FSH (>10 mIU/ml), LH + FSH is used for ovarian stimulation.  For ovarian stimulation in patients with hypogonadotrophic hypogonadism, a combination of LH and FSH is used. Dr Shashwat Jani. 9909944160 2824-Apr-17
  • 29. A. Conventional regimen B. Low dose step up regime C. Step down regime Dr Shashwat Jani. 9909944160 2924-Apr-17
  • 30. Days 7 14 21 28 hCG 150 IU 112.5 IU 75 IU hCG Foll.  10 mm 75-150 U daily 6 12 hCG Foll.  16mm 37.5 IU 75 IU 112.5 IU 150 IU Chronic Low dose Step up regimen Step down Conventional Regime 24-Apr-17 Dr Shashwat Jani. 9909944160 30
  • 31. CC resistant OR CC Failure Cases Started from D2 / D3 75 - 150 IU /day Serial USG for monitoring D 8 S. estradiol Widely accepted protocol . PR up to 30 % Dr Shashwat Jani. 9909944160 3124-Apr-17
  • 32.  Useful in PCOS  AIM : To find the “threshold“ level of FSH which will lead to the development of a single preovulatory follicle.  Less complication  But , unphysiological as FSH is very high in late follicular phase compared to natural cycle. Dr Shashwat Jani. 9909944160 3224-Apr-17
  • 33.  Low starting dose (37.5- 75 units/day )  Stepwise increase in subsequent doses  E2 & USG on D7  D8 E2 > 200 pg/ml OR follicle > 10mm Ct. Same dose.  If E2 or Follicle size not achieved on D8 increase dose by 37.5 IU /day . Dr Shashwat Jani. 9909944160 3324-Apr-17
  • 34.  HMG / FSH 150 IU/day from D2  Continued till Dominant follicle become 10mm on USG  Decrease the dose .  112.5 IU/day for next 3 days  75 IU day till time of HCG. Dr Shashwat Jani. 9909944160 3424-Apr-17
  • 35.  Sequential use of CC f / b FSH or HMG.  CC ( 100 mg ) 1 daily from D2 to D6.  FSH or HMG ( 75 / 150 IU ) on D6 & D8.  TVS on D8 onwards  Additional FSH / HMG given. Dr Shashwat Jani. 9909944160 3524-Apr-17
  • 36.  Higher pregnancy rate than with CC alone .  More cost effective, as the dosage of gonadotrophins is reduced .  Lesser multiple pregnancy rate than with gonadotrophins alone .  Lower incidence of OHSS, as compared to the conventional regime.  Kemmann E, Jones J R. Sequential clomiphene Citrate menotrophin therapy for induction or enhancement of ovulation.Fertil Steril 1983;39:772-9  Dickey R P, Olar T T, Taylor S N, Curole D N, Rye P H . Sequential clomiphene citrate and Human menopausal Gonadotrophin for ovulation induction: comparison to clomiphene citrate alone and human menopausal gonadotrophin alone.. Human Reprod 1993; 8:56- 59Dr Shashwat Jani. 9909944160 3624-Apr-17
  • 37.  Good alternative to CC in patients with unexplained infertility undergoing gonadotrophin stimulated COH cycles combined with IUI therapy.  In a prospective nonrandomized study by Mitwally and Casper it was shown that aromatase inhibition with letrozole reduced the dosage of FSH required for COH without any undesirable antiestrogenic effects, Dr Shashwat Jani. 9909944160 3724-Apr-17
  • 38.  The pregnancy rate achieved was also significantly lower in the CC + FSH group (10.5%) compared with the letrozole + FSH group (19.1%) and FSH only group (18.7%). Dr Shashwat Jani. 9909944160 3824-Apr-17
  • 39.  In almost 15-20 % of cycles of CC or HMG  Due to multi follicular development, Estradiol Increases Premature LH surge Cycle Cancellation. Dr Shashwat Jani. 9909944160 3924-Apr-17
  • 40.  To avoid this endogenous LH interference, Exogenous Gonadotrophins & GnRH analogues are used for OI.  Mainly useful in IVF.  Recent Cochrane review has concluded that GnRH analogues do not significantly improve pregnancy rates in IUI. Dr Shashwat Jani. 9909944160 4024-Apr-17
  • 41.  Act by competitive inhibition of GnRH receptors, which results in rapid decline in FSH /LH levels, thus preventing premature LH surge.  Can be given in a single dose or daily dose regimen. Dr Shashwat Jani. 9909944160 4124-Apr-17
  • 42. 1. Lubeck Protocol: Gonadotrophins are started as usual and antagonist is started when the follicle reaches a size of 14 mm, or from 6 day of stimulation onwards in a dose of 0.25mg / day till the day of HCG injection. Dr Shashwat Jani. 9909944160 42 Diedrich K , Diedrich C , Santos E , Zoll C , Al-Hasani S , Reissmann T , et al. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation . Hum Reprod. 1994; 9:788-791. 24-Apr-17
  • 43. 2. French Protocol : Gonadotrophins are started as usual and a single dose (3 mg) of antagonist is given when serum E2 level is about 150-200 pg/ml and follicular size is 14 mm . Dr Shashwat Jani. 9909944160 43 Olivennes F , Fanchin R , Bouchard P , de Ziegler D , Taieb J , Selva J , et al. . The single or dual administration of the gonadotropin-releasing hormone antagonist Cetrorelix in an in vitro fertilizationembryo transfer program. Fertil Steril. 1994;62:468 24-Apr-17
  • 44. 1. Allows the manipulation of follicular development so that IUI can be avoided at weekends without any detrimental effect on PR. 2. Compared to agonist , it is relatively simple and inexpensive. There is no suppression of oestrogen and the effects are easily reversible. 3. Antagonists are associated with lower rates of OHSS. Dr Shashwat Jani. 9909944160 4424-Apr-17
  • 46.  D2 TVS  Serial TVS from D8  to look for follicular development ( Number & Size ).  Normally follicle grow 2 – 3 mm/day  helps in determining exact time to trigger ovulation  Prevent OHSS  Endometrium: look for thickness & appearance.  Triple line ET of > 9 – 10 mm is ideal . Dr Shashwat Jani. 9909944160 4624-Apr-17
  • 47.  In Natural Cycle : Serum E2 level correlates with development of dominant follicle.  In Stimulated cycle: it reflects the total output of all developing follicle irrespective of size.  Problem : Inconvenience , Cost , daily Prick  Mainly used in Gonadotrophin cycle on D8 , Value > 200 pg/ml  Good response. Dr Shashwat Jani. 9909944160 4724-Apr-17
  • 48.  > 4 follicles of > 16 mm OR > 8 follicles of > 12 mm  Serum Estradiol  > 1500 – 2000 pg / ml Cancel the cycle  If < 1500 pg/ ml  use GnRH analogue to trigger ovulation Dr Shashwat Jani. 9909944160 4824-Apr-17
  • 49.  Premature LH surge is known to occur in 20 to 24% of patients undergoing ovarian stimulation after the leading follicle reaches 16 mm.  The LH surge can be detected either by doing a daily blood or urinary LH assay, once the leading follicle exceeds 16 mm.  When LH surge detected  Inj. HCG given & IUI planned. Dr Shashwat Jani. 9909944160 4924-Apr-17
  • 50.  Ideally 36 -38 after HCG administration OR After Confirmation of Ovulation. 50 Dr Shashwat Jani. 990994416024-Apr-17
  • 51.  The HCG injection is necessary as the LH secreted by the body may not be adequate enough, to induce the necessary maturational changes in all oocytes, if there are many follicles in the ovary.  Numerous urinary LH kits are available to detect LH surge. They are easy to use and are cost effective. Dr Shashwat Jani. 9909944160 5124-Apr-17
  • 52. 24-Apr-17 52 Dr Shashwat Jani. +91 9909944160